ImmunityBio Inc. Share Price Today: Live Updates & Key Insights

ImmunityBio Inc. share price today is $8.55, up -3.97%. The stock opened at $8.96 against the previous close of $8.82, with an intraday high of $9.32 and low of $8.41.

ImmunityBio Inc. Share Price Chart

ImmunityBio Inc.

us-stock
To Invest in {{usstockname}}
us-stock

ImmunityBio Inc. Share Price Performance

$8.55 -0.0397(-3.97%) IBRX at 23 Mar 2026 01:33 PM Biotechnology
Lowest Today 8.41
Highest Today 9.32
Today’s Open 8.96
Prev. Close 8.82
52 Week High 12.43
52 Week Low 1.83
Day’s Range: Low 8.41 High 9.32
52-Week Range: Low 1.83 High 12.43
1 day return -
1 Week return +3.16
1 month return -13.68
3 month return +275.22
6 month return +218.19
1 year return +198.59
3 year return +421.84
5 year return -77.72
10 year return -

ImmunityBio Inc. Institutional Holdings

Vanguard Group Inc 3.19

BlackRock Inc 1.93

Jane Street Group LLC 1.38

Vanguard Total Stock Mkt Idx Inv 1.13

State Street Corp 1.10

State Street® SPDR® S&P® Biotech ETF 0.99

Geode Capital Management, LLC 0.77

Vanguard Small Cap Index 0.76

iShares Russell 2000 ETF 0.70

Two Sigma Investments LLC 0.46

Vanguard Small Cap Growth Index Inv 0.42

Susquehanna International Group, LLP 0.36

Woodline Partners LP 0.34

Morgan Stanley - Brokerage Accounts 0.33

Vanguard Institutional Extnd Mkt Idx Tr 0.33

AlphaCore Capital LLC 0.29

SEB Läkemedelsfond 0.28

Fidelity Small Cap Index 0.28

Charles Schwab Investment Management Inc 0.24

iShares Biotechnology ETF 0.24

Citigroup Inc 0.23

TANG CAPITAL MANAGEMENT LLC 0.23

JPMorgan Chase & Co 0.21

iShares Russell 2000 Growth ETF 0.20

Northern Trust Corp 0.19

State St Russell Sm/Mid Cp® Indx SL Cl I 0.17

UBS Group AG 0.16

Bank of America Corp 0.16

Fidelity Extended Market Index 0.16

Voleon Capital Management LP 0.15

Squarepoint Ops LLC 0.15

Schwab US Small-Cap ETF™ 0.14

Vanguard Russell 2000 ETF 0.14

Skandinaviska Enskilda Banken AB 0.13

Vanguard Health Care ETF 0.10

State St Russell Sm Cap® Indx SL Cl I 0.09

JPM Thematics Genetic Thrps C2 dist USD 0.08

Schwab Small Cap Index 0.07

Blackrock Extended Mkt Fund CF 0.07

iShares Nasdaq US Biotech ETF USD Acc 0.07

ImmunityBio Inc. Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ImmunityBio Inc. Fundamentals

Market Cap 8708.10 M

PB Ratio 0.0

PE Ratio 0.0

Enterprise Value 9003.92 M

Total Assets 501.90 M

Volume 31639947

ImmunityBio Inc. Company Financials

Annual Revenue FY25:113288000 113.3M, FY23:556000 0.6M, FY22:240000 0.2M, FY21:934000 0.9M, FY20:605000 0.6M

Annual Profit FY25:112535000 112.5M, FY23:null 0.0M, FY22:240000 0.2M, FY21:934000 0.9M, FY20:605000 0.6M

Annual Net worth FY25:-351398000 -351.4M, FY23:-458019000 -458.0M, FY22:-417320000 -417.3M, FY21:-349848000 -349.8M, FY20:-224187000 -224.2M

Quarterly Revenue Q4/2025:38285000 38.3M, Q3/2025:32061000 32.1M, Q2/2025:26425000 26.4M, Q1/2025:16517000 16.5M, Q3/2024:6106000 6.1M

Quarterly Profit Q4/2025:41854000 41.9M, Q3/2025:27933000 27.9M, Q2/2025:26289000 26.3M, Q1/2025:16459000 16.5M, Q3/2024:6106000 6.1M

Quarterly Net worth Q4/2025:-61944000 -61.9M, Q3/2025:-67253000 -67.3M, Q2/2025:-92555000 -92.6M, Q1/2025:-129646000 -129.6M, Q3/2024:-85729000 -85.7M

About ImmunityBio Inc. & investment objective

Company Information ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Organisation Biotechnology

Employees 684

Industry Biotechnology

CEO Mr. Richard Gerald Adcock

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ImmunityBio Inc. FAQs

What is the share price of ImmunityBio Inc. today?

The current share price of ImmunityBio Inc. is $8.55.

Can I buy ImmunityBio Inc. shares in India?

Yes, Indian investors can buy ImmunityBio Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy ImmunityBio Inc. shares in India?

You can easily invest in ImmunityBio Inc. shares from India by:

Can I buy fractional shares of ImmunityBio Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ImmunityBio Inc.?

ImmunityBio Inc. has a market cap of $8708.10 M.

In which sector does ImmunityBio Inc. belong?

ImmunityBio Inc. operates in the Biotechnology sector.

What documents are required to invest in ImmunityBio Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of ImmunityBio Inc.?

The PE ratio of ImmunityBio Inc. is N/A and the PB ratio is N/A.